

# Cellular immunotherapy : from stem cell to lymphocyte

Citation for published version (APA):

Huijskens, M. J. A. J. (2015). *Cellular immunotherapy : from stem cell to lymphocyte*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20150212mh>

## Document status and date:

Published: 01/01/2015

## DOI:

[10.26481/dis.20150212mh](https://doi.org/10.26481/dis.20150212mh)

## Document Version:

Publisher's PDF, also known as Version of record

## Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

## General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

[www.umlib.nl/taverne-license](http://www.umlib.nl/taverne-license)

## Take down policy

If you believe that this document breaches copyright please contact us at:

[repository@maastrichtuniversity.nl](mailto:repository@maastrichtuniversity.nl)

providing details and we will investigate your claim.

# Propositions

## **Cellular Immunotherapy From stem cell to lymphocyte**

Mirelle J.A.J. Huijskens  
Maastricht, 12 February 2015

1. Extreme safety measurements concerning novel therapies, like cellular therapy, result in high development costs and thereby reduce progress. Paradoxically, these measurements will therefore possibly result in an increase rather than a decrease in mortality. (valorisation)
2. Vitamin C is required for the generation of T cells *in vitro*. (this thesis)
3. Mesenchymal network formation requires abrogation of thymic crosstalk. (this thesis)
4. Feeder cultures are too heterogeneous to serve as proper system for the generation of cellular products for therapy. (this thesis)
5. *In vitro* lymphoid development requires a more specialized environment compared to myeloid development. (this thesis)
6. Personalised therapy is the treatment for cancer of the future.
7. T cell progenitor therapy alone will not be sufficient to prevent infections in immunocompromised patients.
8. “English literature concentrates on Shakespeare, so orthomolecular therapy concentrates on vitamin C. Let the greats be given their due. The importance of vitamin C cannot be overemphasised.” (Andrew W. Saul)
9. “The game of science is, in principle, without end. He who decides one day that scientific statements do not call for any further test, and that they can be regarded as finally verified, retires from the game.” (Karl Popper)
10. “I’ve found that luck is quite predictable. If you want more luck, take more chances.” (Brian Tracy)